Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds

Free Radical Biology and Medicine

Volumn 39, Issue 5, 2005, Pages 696-703

  Witte, Anne Barbara ^a   Anestål, Karin ^a   Jerremalm, Elin ^a   Ehrsson, Hans ^a   Arnér, Elias S J ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Alkylating agents; Cisplatin; Daunorubicin; Doxorubicin; Glutathione reductase; Oxaliplatin; Selenocysteine; Selenoprotein; Thioredoxin reductase

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; DAUNORUBICIN; DOXORUBICIN; GLUTATHIONE REDUCTASE; MELPHALAN; NITROSOUREA; OXALIPLATIN; PLATINUM DERIVATIVE; SULFONIC ACID DERIVATIVE; THIOREDOXIN REDUCTASE;

ARTICLE; CYTOTOXICITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME SUBSTRATE; PRIORITY JOURNAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTIOXIDANTS; BINDING SITES; BUSULFAN; CHLORAMBUCIL; CISPLATIN; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; GLUTATHIONE REDUCTASE; MELPHALAN; ORGANOPLATINUM COMPOUNDS; RATS; SPECTROPHOTOMETRY; SUBSTRATE SPECIFICITY; THIOREDOXIN REDUCTASE (NADPH); TIME FACTORS;

BRASSICACEAE; MAMMALIA;

EID: 23444435104     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2005.04.025     Document Type: Article

References (57)

1. E.S.J. Arnér, and A. Holmgren Physiological functions of thioredoxin and thioredoxin reductase Eur. J. Biochem. 267 2000 6102 6109
2. J. Nordberg, and E.S.J. Arnér Reactive oxygen species, antioxidants, and the mammalian thioredoxin system Free Radic. Biol. Med. 31 2001 1287 1312
3. K.L. Bloomfield, S.A. Osborne, D.D. Kennedy, F.M. Clarke, and K.F. Tonissen Thioredoxin-mediated redox control of the transcription factor Sp1 and regulation of the thioredoxin gene promoter Gene 319 2003 107 116
4. S. Karimpour, J. Lou, L.L. Lin, L.M. Rene, L. Lagunas, X. Ma, S. Karra, C.M. Bradbury, S. Markovina, P.C. Goswami, D.R. Spitz, K. Hirota, D.V. Kalvakolanu, J. Yodoi, and D. Gius Thioredoxin reductase regulates AP-1 activity as well as thioredoxin nuclear localization via active cysteines in response to ionizing radiation Oncogene 21 2002 6317 6327
5. D.K. Smart, K.L. Ortiz, D. Mattson, C.M. Bradbury, K.S. Bisht, L.K. Sieck, M.W. Brechbiel, and D. Gius Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress Cancer Res. 64 2004 6716 6724
6. J.R. Merwin, D.J. Mustacich, E.G. Muller, G.D. Pearson, and G.F. Merrill Reporter gene transactivation by human p53 is inhibited in thioredoxin reductase null yeast by a mechanism associated with thioredoxin oxidation and independent of changes in the redox state of glutathione Carcinogenesis 23 2002 1609 1615
7. M. Saitoh, H. Nishitoh, M. Fujii, K. Takeda, K. Tobiume, Y. Sawada, M. Kawabata, K. Miyazono, and H. Ichijo Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1 EMBO J. 17 1998 2596 2606
8. K. Anestål, and E.S.J. Arnér Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine J. Biol. Chem. 278 2003 15966 15972
9. D. Padovani, E. Mulliez, and M. Fontecave Activation of class III ribonucleotide reductase by thioredoxin J. Biol. Chem. 276 2001 9587 9589
10. T.C. Laurent, E.C. Moore, and P. Reichard Enzymatic synthesis of deoxyribonucleotides: IV. Isolation and characterization of thioredoxin, the hydrogen donor from Escherichia coli B J. Biol. Chem. 239 1964 3436 3444
11. A. Holmgren Thioredoxin Annu. Rev. Biochem. 54 1985 237 271
12. T.Y. Hui, S.S. Sheth, J.M. Diffley, D.W. Potter, A.J. Lusis, A.D. Attie, and R.A. Davis Mice lacking thioredoxin-interacting protein provide evidence linking cellular redox state to appropriate response to nutritional signals J. Biol. Chem. 279 2004 24387 24393
13. M. Björnstedt, S. Kumar, and A. Holmgren Selenodiglutathione is a highly efficient oxidant of reduced thioredoxin and a substrate for mammalian thioredoxin reductase J. Biol. Chem. 267 1992 8030 8034
14. S. Kumar, M. Björnstedt, and A. Holmgren Selenite is a substrate for calf thymus thioredoxin reductase and thioredoxin and elicits a large non-stoichiometric oxidation of NADPH in the presence of oxygen Eur. J. Biochem. 207 1992 435 439
15. S. Gromer, and J.H. Gross Methylseleninate is a substrate rather than an inhibitor of mammalian thioredoxin reductase. Implications for the antitumor effects of selenium J. Biol. Chem. 277 2002 9701 9706
16. J.M. May, S. Mendiratta, K.E. Hill, and R.F. Burk Reduction of dehydroascorbate to ascorbate by the selenoenzyme thioredoxin reductase J. Biol. Chem. 272 1997 22607 22610
17. A.-K. Rundlöf, M. Janard, A. Miranda-Vizuete, and E.S.J. Arnér Evidence for intriguingly complex transcription of human thioredoxin reductase 1 Free Radic. Biol. Med. 36 2004 641 656
18. A.-K. Rundlöf, M. Carlsten, and E.S.J. Arnér The core promoter of human thioredoxin reductase 1: cloning, transcriptional activity and Oct-1, Sp1 and Sp3 binding reveal a housekeeping-type promoter for the ARE-regulated gene J. Biol. Chem. 276 2001 30542 30551
19. S.R. Lee, J.R. Kim, K.S. Kwon, H.W. Yoon, R.L. Levine, A. Ginsburg, and S.G. Rhee Molecular cloning and characterization of a mitochondrial selenocysteine-containing thioredoxin reductase from rat liver J. Biol. Chem. 274 1999 4722 4734
20. A. Miranda-Vizuete, A.E. Damdimopoulos, J.R. Pedrajas, J.A. Gustafsson, and G. Spyrou Human mitochondrial thioredoxin reductase cDNA cloning, expression and genomic organization Eur. J. Biochem. 261 1999 405 412
21. Q.A. Sun, L. Kirnarsky, S. Sherman, and V.N. Gladyshev Selenoprotein oxidoreductase with specificity for thioredoxin and glutathione systems Proc. Natl. Acad. Sci. USA 98 2001 3673 3678
22. A. Holmgren Bovine thioredoxin system. Purification of thioredoxin reductase from calf liver and thymus and studies of its function in disulfide reduction J. Biol. Chem. 252 1977 4600 4606
23. M. Luthman, and A. Holmgren Rat liver thioredoxin and thioredoxin reductase: purification and characterization Biochemistry 21 1982 6628 6633
24. L. Zhong, E.S.J. Arnér, J. Ljung, F. Åslund, and A. Holmgren Rat and calf thioredoxin reductase are homologous to glutathione reductase with a carboxyl-terminal elongation containing a conserved catalytically active penultimate selenocysteine residue J. Biol. Chem. 273 1998 8581 8591
25. E.S.J. Arnér, H. Sarioglu, F. Lottspeich, A. Holmgren, and A. Böck High-level expression in Escherichia coli of selenocysteine-containing rat thioredoxin reductase utilizing gene fusions with engineered bacterial-type SECIS elements and co-expression with the selA, selB and selC genes J. Mol. Biol. 292 1999 1003 1016
26. O. Rengby, L. Johansson, L.A. Carlson, E. Serini, A. Vlamis-Gardikas, P. Kårsnäs, and E.S.J. Arnér Assessment of production conditions for efficient use of Escherichia coli in high-yield heterologous recombinant selenoprotein synthesis Appl. Environ. Microbiol. 70 2004 5159 5167
27. T. Sandalova, L. Zhong, Y. Lindqvist, A. Holmgren, and G. Schneider Three-dimensional structure of a mammalian thioredoxin reductase: implications for mechanism and evolution of a selenocysteine-dependent enzyme Proc. Natl. Acad. Sci. USA 98 2001 9533 9538
28. L. Zhong, E.S.J. Arnér, and A. Holmgren Structure and mechanism of mammalian thioredoxin reductase: The active site is a redox-active selenolthiol/selenenylsulfide formed from the conserved cysteine-selenocysteine sequence Proc. Natl. Acad. Sci. USA 97 2000 5854 5859
29. S. Gromer, S. Urig, and K. Becker The thioredoxin system-From science to clinic Med. Res. Rev. 24 2004 40 89
30. E.S.J. Arnér, L. Zhong, and A. Holmgren Preparation and assay of mammalian thioredoxin and thioredoxin reductase Methods Enzymol. 300 1999 226 239
31. N. Cenas, H. Nivinskas, Z. Anusevicius, J. Sarlauskas, F. Lederer, and E.S.J. Arnér Interactions of quinones with thioredoxin reductase-A challenge to the antioxidant role of the mammalian selenoprotein J. Biol. Chem. 279 2004 2583 2592
32. E.S.J. Arnér, H. Nakamura, T. Sasada, J. Yodoi, A. Holmgren, and G. Spyrou Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase; glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex Free Radic. Biol. Med. 31 2001 1170 1178
33. J. Nordberg, L. Zhong, A. Holmgren, and E.S.J. Arnér Mammalian thioredoxin reductase is irreversibly inhibited by dinitrohalobenzenes by alkylation of both the redox active selenocysteine and its neighboring cysteine residue J. Biol. Chem. 273 1998 10835 10842
34. S. Gromer, L.D. Arscott, C.H. Williams, R.H. Schirmer, and K. Becker Human placenta thioredoxin reductase: Isolation of the selenoenzyme, steady state kinetics; inhibition by therapeutic gold compounds J. Biol. Chem. 273 1998 20096 20101
35. K. Becker, S. Gromer, R.H. Schirmer, and S. Müller Thioredoxin reductase as a pathophysiological factor and drug target Eur. J. Biochem. 267 2000 6118 6125
36. L. Engman, I. Cotgreave, M. Angulo, C.W. Taylor, G.D. Paine-Murrieta, and G. Powis Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents Anticancer Res. 17 1997 4599 4605
37. L. Engman, T. Kandra, A. Gallegos, R. Williams, and G. Powis Water-soluble organotellurium compounds inhibit thioredoxin reductase and the growth of human cancer cells Anticancer Drug Des. 15 2000 323 330
38. J. Dessolin, C. Biot, and E. Davioud-Charvet Bromination studies of the 2,3-dimethylnaphthazarin core allowing easy access to naphthazarin derivatives J. Org. Chem. 66 2001 5616 5619
39. K.U. Schallreuter, F.K. Gleason, and J.M. Wood The mechanism of action of the nitrosourea anti-tumor drugs on thioredoxin reductase, glutathione reductase and ribonucleotide reductase Biochim. Biophys. Acta 1054 1990 14 20
40. S. Gromer, R.H. Schirmer, and K. Becker The 58 kDa mouse selenoprotein is a BCNU-sensitive thioredoxin reductase FEBS Lett. 412 1997 318 320
41. M.D. Colvin R.C. Bast Jr. D.W. Kufe R.E. Pollock R.R. Weichselbaum J.F. Holland III E. Frei T.S. Gansler Alkylating agents and platinum antitumor compounds, in cancer medicine 2000 Decker Hamilton, Ontario Chapter 48
42. H.C. Ehrsson, I.B. Wallin, A.S. Andersson, and P.O. Edlund Cisplatin, transplatin, and their hydrated complexes: separation and identification using porous graphitic carbon and electrospray ionization mass spectrometry Anal. Chem. 67 1995 3608 3611
43. S. Gromer, H. Merkle, R.H. Schirmer, and K. Becker Human placenta thioredoxin reductase: preparation and inhibitor studies Methods Enzymol. 347 2002 382 394
44. B.L. Mau, and G. Powis Mechanism-based inhibition of thioredoxin reductase by antitumor quinoid compounds Biochem. Pharmacol. 43 1992 1613 1620
45. A.G. Bosanquet Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays: general considerations, the nitrosoureas and alkylating agents Cancer Chemother. Pharmacol. 14 1985 83 95
46. J.R. Yachnin, I. Wallin, R. Lewensohn, F. Sirzen, and H. Ehrsson The kinetics and cytotoxicity of cisplatin and its monohydrated complex Cancer Lett. 132 1998 175 180
47. C.R. Culy, D. Clemett, and L.R. Wiseman Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies Drugs 60 2000 895 924
48. E.S.J. Arnér, M. Björnstedt, and A. Holmgren 1-Chloro-2,4-dinitrobenzene is an irreversible inhibitor of human thioredoxin reductase: loss of thioredoxin disulfide reductase activity is accompanied by a large increase in NADPH oxidase activity J. Biol. Chem. 270 1995 3479 3482
49. M. Tonetti, A. Gasparini, M. Giovine, U. Benatti, and A. De Flora Enhanced intracellular activation of carboplatin in hemoglobin-synthesizing versus undifferentiated erythroleukemic cells Biochem. Biophys. Res. Commun. 182 1992 760 766
50. W. De Neve, F. Valeriote, E. Tapazoglou, C. Everett, A. Khatana, and T. Corbett Discrepancy between cytotoxicity and DNA interstrand crosslinking of carboplatin and cisplatin in vivo Invest. New Drugs 8 1990 17 24
51. A. Mandic, K. Viktorsson, L. Strandberg, T. Heiden, J. Hansson, S. Linder, and M.C. Shoshan Calpain-mediated Bid cleavage and calpain-independent Bak modulation: two separate pathways in cisplatin-induced apoptosis Mol. Cell Biol. 22 2002 3003 3013
52. A. Mandic, J. Hansson, S. Linder, and M.C. Shoshan Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling J. Biol. Chem. 278 2003 9100 9106
53. B.L. Mau, and G. Powis Inhibition of cellular thioredoxin reductase by diaziquone and doxorubicin. Relationship to the inhibition of cell proliferation and decreased ribonucleotide reductase activity Biochem. Pharmacol. 43 1992 1621 1627
54. P.A. Karplus, R.L. Krauth-Siegel, R.H. Schirmer, and G.E. Schulz Inhibition of human glutathione reductase by the nitrosourea drugs 1,3-bis(2-chloroethyl)-1-nitrosourea and 1-(2-chloroethyl)-3-(2-hydroxyethyl)-1- nitrosourea. A crystallographic analysis Eur. J. Biochem. 171 1988 193 198
55. C.M. Jochheim, and T.A. Baillie Selective and irreversible inhibition of glutathione reductase in vitro by carbamate thioester conjugates of methyl isocyanate Biochem. Pharmacol. 47 1994 1197 1206
56. K. Becker, and R.H. Schirmer 1,3-Bis(2-chloroethyl)-1-nitrosourea as thiol-carbamoylating agent in biological systems Methods Enzymol. 251 1995 173 188
57. L.D. Arscott, S. Gromer, R.H. Schirmer, K. Becker, and C.H. Williams Jr. The mechanism of thioredoxin reductase from human placenta is similar to the mechanisms of lipoamide dehydrogenase and glutathione reductase and is distinct from the mechanism of thioredoxin reductase from Escherichia coli Proc. Natl. Acad. Sci. USA 94 1997 3621 3626